Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study-Reference-Cited by-同舟云学术

Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study

Published:2023-07-20 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Guo Wenwen,Cao Yigeng,Liu Jia,Zheng Xinhui,Wang Mingyang^ORCID,Zheng Yawei,Zhang Xiaoyu,Zhai Weihua,Chen Xin,Zhang Rongli,Ma Qiaoling,Yang Donglin^ORCID,Wei Jialin,He Yi^ORCID,Pang Aiming,Feng Sizhou,Han Mingzhe,Jiang Erlie^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-02045-w.pdf

Reference11 articles.

1. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119:34–43.

2. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147–56.

3. Haydu JE, Ferrando AA. Early T-cell precursor acute lymphoblastic leukaemia. Curr Opin Hematol. 2013;20:369–73.

4. Ishida H, Kato M, Kawahara Y, Ishimaru S, Najima Y, Kako S, et al. Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation. Hematol Oncol. 2022;40:457–68.

5. Yasuda S, Najima Y, Konishi T, Yamada Y, Nagata A, Takezaki T, et al. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. Leuk Res. 2021;108:106627.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chidamide maintenance therapy after allo-HSCT in SET-NUP214 fusion positive T-ALL patients: A report of two cases;Transplant Immunology;2024-12

2. Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT;Annals of Hematology;2024-06-22

3. Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma;Bone Marrow Transplantation;2024-01-23

4. The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation;Frontiers in Oncology;2023-10-13